Statistics for Avalo Therapeutics, (id:5871 AVTX)

Valuation metrics

Market cap

106.00M

Enterprise value

21.73M

Trailing P/E (ttm)

0.11

Forward P/E

-2.16

PEG ratio

-2.16

Price/Sales (ttm)

129.26

Price/Book (mrq)

4.65

Enterprise Value/Revenue

26.51

Enterprise Value/EBITDA

-0.70

Overview

Shares outstanding

10.46M

Float

5.05M

Shares short

10.06K

% Held by insiders

0.06%

% Held by institutions

0.65%

Average volume (10 days)

95.95K

Average volume (90 days)

Price summary

52-Week low

3.95

52-Week high

34.46

52-Week change

-108.49%

Beta

1.03

50-Day moving average

11.06

200-Day moving average

10.50

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

December 29th, 2023

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

33.26%

Operating margin

-5,165.06%

Operational effectiveness

Return on assets

-30.64%

Return on equity

-42.52%

Income statement

Revenue (ttm)

0.40

Revenue per share (ttm)

0.40

Quarterly revenue growth (yoy)

Gross profit (ttm)

640.00K

EBITDA

-31,167,000.00

Net income to common (ttm)

-8,135,000.00

Diluted EPS (ttm)

94.42

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

81.86M

Total cash per share (mrq)

7.88

Total debt (mrq)

1.63M

Total Debt/Equity (mrq)

7.18

Current ratio (mrq)

142.00%

Book value per share (mrq)

2.18

Cash flow

Cash flow statement

-36,778,000.00

Levered free cash flow (LFCF)

39.64M